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ABSTRACT 
The p53 transcription factor is activated by cellular stress. This triggers transcriptional 
activation of a number of p53 target genes, leading to responses such as cell cycle arrest 
and/or induction of apoptosis. Wig-1 is a p53 target gene and its RNA and protein levels 
increase after p53 protein activation. Wig-1 is a RNA-binding zinc finger protein with 
affinity to double-stranded RNA and it is involved in regulation of mRNA stability. In this 
thesis, I focused on the characterization of the Wig-1 protein function, on the identification of 
its bound RNA targets and on the elucidation of the biological implication of their regulation.  
We found that Wig-1 belongs to the group of proteins known as AU-rich element binding 
proteins (ARE-BPs) and plays a role in regulation of post-transcriptional gene expression 
targeting mRNAs containing AU-rich elements (ARE) in their 3’UTRs. In paper I, we 
showed that Wig-1 stabilizes p53 mRNA by preventing its deadenylation and that this 
regulation is mediated through direct binding of Wig-1 to a U-rich element (a subgroup of 
AREs) in the 3’UTR of p53 mRNA. In paper II, we found that Wig-1 binds to N-Myc mRNA 
and positively regulates it through an ARE in the 3’UTR. We also showed that Wig-1 
knockdown in neuroblastoma cells carrying amplified N-Myc leads to cell differentiation and 
repressed cell growth as a consequence of Wig-1 regulation of N-Myc RNA stability. In 
paper III we performed microarray gene expression analysis after Wig-1 knockdown in the 
colon cancer cell line HCT116 and found a large group of mRNAs that are directly or 
indirectly affected by Wig-1. We also discovered that Wig-1 knockdown is affecting cell 
cycle and the apoptotic response to stress through regulation of the p53 target genes FAS and 
14-3-3!. We could demonstrate that FAS mRNA regulation is dependent on Wig-1 binding 
to an ARE on FAS 3’UTR. At last, in paper IV, we performed RNA-immunoprecipitation 
followed by deep sequencing in order to identify genome-wide Wig-1 associated mRNAs. 
The analysis revealed that Wig-1 binds a large number of mRNAs most of which are 
functionally connected to the cell cycle pathway. Moreover, sequence analysis revealed that 
AREs are highly enriched in the 3’UTRs of these Wig-1-bound mRNAs.  
In conclusion, this thesis provides a comprehensive view of the RNA-binding properties of 
Wig-1 and helps to better define the Wig-1-RNA interaction network. Our data establish 
Wig-1 as an AU-rich element binding protein involved in regulation of post-transcriptional 
gene expression of many mRNAs such as the p53 tumor suppressor and its transcriptional 
target FAS, the N-Myc oncogene and several other targets, ultimately affecting cell cycle 
progression and cell proliferation. Moreover, we provide additional insights into preferred 
Wig-1 RNA binding motifs. Additionally, as Wig-1 is a target of the p53 transcription factor, 
we gained further understanding of the p53-mediated tumor suppression through its target 
Wig-1, extending the frontiers of gene expression control from transcriptional to post-
transcriptional level. 
 
 LIST OF SCIENTIFIC PAPERS 
 
I. Anna Vilborg, Jacob A. Glahder, Margareta T. Wilhelm, Cinzia Bersani, Martin 
Corcoran, Salah Mahmoudi, Maiken Rosenstierne, Dan Grandér, Marianne Farnebo, 
Bodil Norrild, and Klas G. Wiman. 
The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. 
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15756-61 
II. Anna Vilborg, Cinzia Bersani, Malin Wickström, Lova Segerström, Per Kogner, 
Klas G. Wiman. 
Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth. 
Cell Death Dis. 2012 Apr 19;3:e298 
III. Cinzia Bersani, Lidi Xu, Anna Vilborg, Weng-Onn Lui, Klas G. Wiman. 
Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-
3-3!. 
Oncogene. 2014 Aug 28;33(35):4407-17 
IV. Cinzia Bersani, Mikael Huss, Stefania Giacomello, Lidi Xu, Anna Vilborg, Andrey 
Alexeyenko, Weng-Onn Lui and Klas G. Wiman 
Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis. 
Manuscript 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Related publications 
 
Anna Vilborg, Cinzia Bersani, Margareta T. Wilhelm, Klas G. Wiman. 
The p53 target Wig-1: a regulator of mRNA stability and stem cell fate? 
Cell Death Differ. 2011 Sep;18(9):1434-40. Review. 
  
CONTENTS 
1! Introduction ...................................................................................................................... 1!
1.1! Cancer – a brief overview ..................................................................................... 1!
1.2! Wig-1 – gene and protein structure ....................................................................... 2!
1.3! Wig-1 protein function .......................................................................................... 4!
1.4! Transcriptional and epigenetic Wig-1 regulation ................................................. 5!
1.5! Post-transcriptional Wig-1 regulation ................................................................... 7!
1.6! Post-translational Wig-1 regulation .................................................................... 10!
1.7! Wig-1 in physiology and disease ........................................................................ 11!
1.7.1! Wig-1 in cancer ....................................................................................... 11!
1.7.2! Wig-1 in stem cell maintenance and differentiation .............................. 12!
1.7.3! Wig-1 in the brain ................................................................................... 13!
1.8! The p53 tumor suppressor ................................................................................... 14!
1.8.1! p53 and cell fate decision ....................................................................... 15!
1.8.2! Regulation of p53 at RNA level ............................................................. 16!
1.9! The N-Myc oncogene .......................................................................................... 16!
1.10! FAS ..................................................................................................................... 17!
1.11! Post-transcriptional regulation of gene expression ............................................ 18!
1.11.1! AU-rich elements .................................................................................... 19!
1.11.2! AU-rich element binding proteins .......................................................... 20!
1.11.3! AU-rich element mediated mRNA decay (AMD) ................................. 20!
1.11.4! Importance of RNA 2D and 3D structure .............................................. 21!
1.12! Protein-RNA interaction analysis and high-throughput techniques .................. 22!
2! Aim of this thesis ........................................................................................................... 25!
3! Results and discussion ................................................................................................... 26!
3.1! Paper I .................................................................................................................. 26!
3.2! Paper II ................................................................................................................. 27!
3.3! Paper III ............................................................................................................... 28!
3.4! Paper IV ............................................................................................................... 30!
4! Conclusion and final directions ..................................................................................... 33!
5! Acknowledgements ........................................................................................................ 37!
6! References ...................................................................................................................... 39!
 
 LIST OF ABBREVIATIONS 
4-SU 4-thiouridine 
5-Fu 5-fluorouracil 
5’TOP 5" terminal oligopyrimidine 
6-SG 6-thioguanosine 
ADAR adenosine deaminase, RNA-specific 
AGO argonaute protein 
AKT3 v-akt murine thymoma viral oncogene homolog 3 
AluSx Arthrobacter luteus element Sx 
AluY Arthrobacter luteus element Y 
AMD AU-rich element mediated decay 
AMD1 adenosylmethionine decarboxylase 1 
Apo1/CD95 apoptosis antigen 1/cluster of differentiation 95 
APP amyloid precursor protein 
ARE adenylate-uridylate rich element 
ARE-BP adenylate-uridylate rich elements binding protein 
ARF ADP ribosylation factor 
ASD autism spectrum disorder 
ASO antisense oligonucleotide 
ASPP1 apoptosis-stimulating protein of p53, 1 
ASPP2 apoptosis-stimulating protein of p53, 2 
AUF1 AU-rich element RNA-binding protein 1 
AUTS2 autism susceptibility candidate 2 
Bax BCL2-associated X protein 
Bid BH3 interacting domain death agonist 
Bmi-1 B lymphoma Mo-MLV insertion region 1 homolog 
BRAC1 breast cancer 1, early onset 
BRAF v-raf murine sarcoma viral oncogene homolog B 
BRD-Box bearded-box 
  
BRD7 bromodomain containing 7 
BRF-1/2 B -related factor 1/2 
BRK baby rat kidney 
Brn3 brain-specific homeobox/POU domain protein 3 
C2H2 cys2/his2-type zinc finger 
CAV1 caveolin 1 
CCNG1 cyclin G1 
Ccr4-Not chemokine (C-C motif) receptor 4 - negative regulator of 
transcription 
CDKN1A cyclin-dependent kinase inhibitor 1A 
CDKN2A cyclin-dependent kinase inhibitor 2A 
CHEK1 checkpoint kinase 1 
ChIP chromatin immunoprecipitation 
CLIP cross-linking and immunoprecipitation 
CNOT6 CCR4-NOT transcription complex, subunit 6 
CNS central nervous system 
Co-IP co-immunoprecipitation 
CpG cytosine-phosphate-guanine 
CRD coding region determinant 
DAP5 death-associated protein 5 
Dcp1/Dcp2 decapping mRNA 1/ decapping mRNA 2 
DD death domain 
DICER1 double-stranded RNA-specific endoribonuclease 1 
DNA deoxyribonucleic acid  
dsRNA double stranded RNA 
DYRK2 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 
EIF4E eukaryotic translation initiation factor 4E 
ELF1 E74-like factor 1 (ets domain transcription factor) 
ESC embryonic stem cell 
EWS Ewing sarcoma RNA binding protein 1 
FADD FAS-associated death domain-containing protein 
FAS FAS cell surface death receptor 
FASL FAS cell surface death receptor ligand 
GC guanine-cytosine 
GU-rich guanylate-uridylate-rich  
GUS glucuronidase 
H3K27me3 tri-methylation of lysine 27 on histone H3 
H3K36me3 tri-methylation of lysine 36 on histone H3 
H3K4me3 tri-methylation of lysine 4 on histone H3 
hCAS/CSE1L human cellular apoptosis susceptibility/ chromosome segregation 1-
like protein 
HIF1A hypoxia inducible factor 1, alpha subunit 
HIPK2 homeodomain interacting protein kinase 2 
HITS high-throughput sequencing 
hnRNP D heterogeneous nuclear ribonucleoprotein D 
hnRNPA2/B1 heterogeneous nuclear ribonucleoprotein A2/B1 
hnRNPC1/C2 heterogeneous nuclear ribonucleoprotein C1/C2 
HuD human antigen D 
HuR human antigen R 
Hzf hematopoietic zinc finger 
iASSP inhibitor of apoptosis stimulating protein of p53 
iCLIP individual-nucleotide resolution CLIP 
IMMP2L inner mitochondrial membrane peptidase 2 like 
INF# interferon beta 
IRE iron responsive elements 
IRES internal ribosome entry site 
JAZ just another zinc finger protein 
KRAS Kirsten rat sarcoma viral oncogene homolog 
KSRP KH type-splicing regulatory protein 
L-DOPA levo- dihydroxyphenylalanine 
LocARNA local alignment of RNA 
m7G-cap 7-methylguanylate cap 
  
MAD2L1 mitotic arrest deficient 2-like protein 1 
MAX MYC associated factor X 
MDM2 mouse double minute 2 human homolog 
MDM4 mouse double minute 4 human homolog 
miRNA microRNA 
mRNA messenger RNA 
MTHFD2 methylenetetrahydrofolate dehydrogenase 2 
MYST MOZ, YBF2/SAS3, SAS2 and TIP60 protein 1 
N-Myc v-myc avian myelocytomatosis viral oncogene neuroblastoma 
derived homolog 
NGF nerve growth factor 
NHGRI national human genome research institute 
NPY neuropeptide Y 
NRF1 nuclear respiratory factor 1 
ORF open reading frame 
p53AIP1 tumor protein p53 regulated apoptosis inducing protein 1 
PAG608 p53-activated gene 608 
Pan2/Pan3 PABP1 dependent poly A specific ribonuclease subunit 2/3 
PAR-CLIP photoactivatable- ribonucleoside-enhanced CLIP 
PB processing bodies 
PCR polymerase chain reaction 
Pdcd4 programmed cell death 4 
Perp p53 apoptosis effector related to PMP22 
PIG3 p53-induced gene 3 
PIK3CA phosphatidyl inositol-3-kinase, catalytic subunit alpha 
PM-Scl75 polymyositis/scleroderma autoantigen 75 KDa 
PPP2CB protein phosphatase 2, catalytic subunit, beta isozyme 
PRC2 polycomb repressive complex 2 
PSF polypyrimidine tract-binding protein (PTB)-associated splicing factor 
PTB polypyrimidine tract-binding protein 
PTEN phosphatase and tensin homolog 
PTM post-translational modification 
PUMA p53 up-regulated modulator of apoptosis 
RBM5 RNA binding motif protein 5 
RBP RNA-binding protein 
RE response element 
RIP RNA immunoprecipitation 
RISC RNA-induced silencing complex 
RITA reactivation of p53 and induction of tumor cell apoptosis 
RMI1 recQ mediated genome instability 1 
RNA ribonucleic acids 
RNA-FISH ribonucleic acid - fluorescence in situ hybridization 
RNPC1 RNA-binding region (RNP1, RRM) containing 1 
ROBO2 roundabout, axon guidance receptor, homolog 1 
RPL26 ribosomal protein L26 
RRM RNA recognition motif 
SECIS selenocysteine insertion sequence 
Seq sequencing 
SF3A1 splicing factor 3a, subunit 1 
SG stress granules 
siRNA small interfering RNA 
SOX2 SRY (sex determining region Y)-box 2 
SPI1 spleen focus forming virus (SFFV) proviral integration oncogene 
TARBP2 trans-activation-responsive RNA-binding protein 2 
TERC telomerase RNA component 
TF transcription factor 
TIA1 T-cell-restricted intracellular antigen-1 
TIAL1/TIAR TIA1 cytotoxic granule-associated RNA-binding protein-like 1 
TNF tumor necrosis factor 
TP53 tumor protein p53 
TP63 tumor protein p63 
TTP tristetraprolin 
  
uORF upstream open reading frame 
UTR untranslated region 
VEGF vascular endothelial growth factor 
Wig-1 wild-type p53 induced gene 1 
WNT1 wingless-type MMTV integration site family, member 1 
Xnr1 5'-3' Exoribonuclease 1 
YB1 Y box binding protein 1 
ZMAT3 zinc finger, matrin-type 3 
 

  1 
1 INTRODUCTION 
 
1.1 CANCER – A BRIEF OVERVIEW 
 
Cancer is a widespread term used to indicate diseases in which abnormal cells divide in an 
uncontrolled way and are able to invade other tissues (metastasis). Many people consider 
cancer as one disease. In reality, there are about 200 known types of cancer. They differ in 
behavior, in growth rate, in their response to treatment and in their genetic signatures. But 
they also have common features which have been summarized by Hanahan and Weinberg in 
[1]. In summary cancer cells can: (1) stimulate their own growth; (2) ignore anti-proliferative 
signals; (3) resist their own programmed cell death (apoptosis); (4) stimulate the growth of 
blood vessels to supply nutrients to tumors (angiogenesis); (5) multiply endlessly; and (6) 
invade confined tissue and spread to distant sites (metastasis). Obtaining the last of these 
features is what distinguishes a tumor form being “benign” to being “malignant”. Moreover, 
Hanahan and Weinberg published in 2011 an updated review including four additional cancer 
hallmarks [2]. The new list includes also: (7) the ability to deregulate normal cell metabolic 
processes; (8) the ability to evade the immune system surveillance; (9) genomic instability 
and high mutation rate; and (10) the ability to induce tumor-associated inflammatory 
response, which paradoxically promotes tumor progression rather than inhibition.  
To answer the question “Why do people get cancer?” we should start by saying that the 
average human body is made up of about sixty trillion cells. Some of these cells divide 
regularly to replace damaged cells in an organized and controlled way. Indeed, our body 
forms billions of new cells every day after a division of a preexisting cell and from time to 
time mistakes happen – i.e. DNA mutations. These errors are not that uncommon, but 
thankfully, our immune system recognizes these cells and repairs or eliminates them. 
Moreover, a cell doesn’t become cancerous overnight or as result of a single mutation. 
Instead, it is estimated that a normal cell needs to accumulate up to 10 “driver” mutations, 
meaning mutations that confer growth advantage on the cells carrying them, in order to 
become a cancer cell [3]. About 500 of the ~20,000 protein coding genes in the human 
genome have been found to be mutated and seem to contribute to cancer development [4].  
Two of the main categories of genes that play a role in cancer are oncogenes and tumor 
suppressor genes. Oncogenes are those genes that typically control cell proliferation and if 
mutated can push cell cycle forward and also rescue cells from undergo apoptosis. Tumor 
suppressors on the other hand are those genes that restrict cellular growth and division and if 
mutated they prevent cells to stop from growing and to respond to pro-apoptotic signals [1]. 
According to The Cancer Genome Atlas (http://cancergenome.nih.gov), commonly mutated 
or altered oncogenes comprise KRAS (mutated in 95% of pancreatic adenocarcinomas and 
40% to 50% of colorectal tumors), PIK3CA (mutated in 49% of uterine corpus endometrial 
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carcinoma and 34% of breast carcinomas), Myc (translocated in all cases of Burkitt’s 
lymphomas and amplified in 42% of ovarian cancers) and BRAF (mutated in 60% of 
melanomas and thyroid carcinomas). Commonly mutated tumor-suppressors include TP53 
(mutated in 94% of ovarian carcinomas and 90% of lung squamous cell carcinoma), 
CDKN2A (loss in about 66% of glioblastomas and 54% of bladder carcinomas), PTEN (loss 
in 40% of prostate cancer and mutated in 64% of Uterine Corpus Endometrial Carcinoma) 
and BRAC1 (mutated in about 50% of all hereditary breast cancer).  
 
1.2 WIG-1 – GENE AND PROTEIN STRUCTURE 
 
Wig-1 (for wild-type p53-induced gene 1, also known as ZMAT3 or PAG608) is an RNA 
binding protein identified as a p53 transcriptional target gene in 1997. Through a PCR-based 
differential display technique Wig-1 mRNA was found to be induced by wild type p53 
expressed from the temperature-sensitive mutant p53 construct in mouse [5] and in rat [6]. 
Four years later the human Wig-1 was also cloned and found to be located in chromosome 
3q26.32 (chr3: 178735011-178789656 – hg19) [7, 8]. There are two transcript variants of the 
Wig-1 gene in human. Isoform 1 (NM_022470) is 8995 nucleotides long, contains 6 exons 
and corresponds to a protein of 289 amino acids. Isoform 2 (NM_152240) is 9113 
nucleotides long, contains 7 exons and corresponds to a protein of 288 amino acids.  
The two isoforms have different 5’UTR sequences: the first isoform has a 331 bps long 
5’UTR while the second isoform has a 452 bps 5’UTR and contains an IRES element (361-
452) suggesting that the translation of the two isoforms might be differently regulated. 
Moreover, Wig-1 contains two in-frame ATG and one upstream out-of-frame ATG. The full-
length protein is translated from the first in-frame ATG; twenty amino acids downstream of 
it, the second in-frame ATG can also be used for translational initiation. This can happen if 
the upstream out-of-frame ATG is used, giving rise to an uORF that terminates in between 
the first and second in-frame ATG, thus allowing the translation of the shorter of the Wig-1 
species that lacks the first 20 amino acids. These two Wig-1 species are both detectable and 
clearly visible on Western blot analysis using an antibody raised against the full length 
protein; moreover, it seems that they might have distinct functions, as supported by the fact 
that their expression changes depending on the conditions, for example after p53-dependent 
Wig-1 induction upon stress by DNA damaging agents (Hellborg et al, unpublished results). 
Human Wig-1 has a perfect consensus p53 response element (RE) on intron 1 (2455 bps 
upstream of the translation start codon). See Figure 1. Induction of p53 by doxorubicin and 
Nutlin in U2OS cells or RITA, Nutlin and 5-Fu in MCF7 cells lead to p53 binding to its RE 
on Wig-1 gene (Chip-Seq analysis) and increase in Wig-1 expression levels [9, 10]. 
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The Wig-1 3’UTR is 7794 bp long and contains five polyadenylation (poly(A)) signals 
(position 1581, 4950, 6771, 7283, 7764), fourteen AU-rich elements (ARE), a SECIS type I 
and a SECIS type II, a BRD-Box, a GY-Box, an AluSx and AluY (Figure 2). All these 
elements are important RNA regulatory motifs and they will be explained in detail in 
paragraph 1.5. 
 
 
Figure 2: Regulatory elements embedded on Wig-1 3'UTR 
 
The Wig-1 protein contains a nuclear localization signal (aa 194-210) and three zinc fingers 
(ZFs) of the Cys2His2 type (aa 72-94, 149-171, 247-269). The ZFs are characterized by an 
uncommon inter-histidine distance (five amino acids instead of the usual three to four). 
Additionally, the distance between the ZFs is also longer than what observed for other ZFs 
(56-75 amino acids instead of the common six to eight) (Figure 2a). 
Wig-1 is a highly conserved protein, especially the zinc-fingers that are almost completely 
conserved from human to amoeba, a unicellular eukaryote that diverged from human lineage 
about 1.5 billion years ago [11, 12] (Figure 2b). Human and mouse Wig-1 share 87% identity 
in the whole protein sequence, 100% identity in the first and second zinc fingers and 97% 
identity in the third zinc-finger. The zinc-fingers are the regions that show higher 
conservation among various species (http://www.uniprot.org) [12, 13].  
Wig-1 zinc fingers are characterized by an unusual structure that is comparable to those of a 
small group of double stranded RNA (dsRNA) binding protein named JAZ. JAZ was the 
founder of a new class of C2H2-type zinc finger proteins; it has almost no affinity for DNA 
or single-stranded RNA, but binds preferentially to double-stranded RNA (dsRNA) [14]. The 
Figure 1: Sequence of the p53 response element on Wig-1 promoter 
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structural similarity between Wig-1 and JAZ led to the discovery that Wig-1 is also an RNA 
binding protein [15].  
 
 
Figure 3: Wig-1 protein structure and Zinc-Fingers alignments 
 
1.3  WIG-1 PROTEIN FUNCTION 
 
Wig-1 is a RNA binding protein that preferentially binds double-stranded RNA (dsRNA).  
Mutational studies showed that the first and second zinc fingers of Wig-1 are required to 
maintain dsRNA binding [5, 13]. Wig-1 binds to dsRNA longer than $ 23 bps, although it 
can also bind shorter siRNA/miRNA-like (carrying 2 nt 3"-protruding ends) dsRNA (21bps) 
in vitro, but with less affinity [16].  
As previously mentioned Wig-1 is a transcriptional target of the p53 tumor suppressor and 
this suggests that it might be involved in the p53 response to cellular stress. Indeed, Wig-1 
inhibits cell growth in a colony formation assay [8, 16]. Remarkably, both Wig-1 
overexpression and knockdown has a negative effect on cell growth indicating that Wig-1 
levels are finely regulated and maintained well-balanced [17]. 
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Wig-1 protein has been shown to interact with a number of other proteins [17-21]. Table 1 
summarizes these data. 
 
Table 1: List of Wig-1 interacting proteins 
 
 
1.4 TRANSCRIPTIONAL AND EPIGENETIC WIG-1 REGULATION 
 
Human Wig-1 has a perfect consensus p53 RE on its first intron (see above). Moreover, it has 
been shown that BRD7 transcriptional co-factor is necessary for p53 transcriptional activation 
of Wig-1 and that BRD7 knockdown lead to decreased Wig-1 levels [22]. Additionally, data 
extracted from the Encyclopedia of DNA Elements (ENCODE) Consortium, an international 
collaboration of research groups funded by the National Human Genome Research Institute 
(NHGRI), revealed that Wig-1 promoter is bound by at least 16 more transcription factor 
(Table 2) [23]. These data, together with the evidence that Wig-1 is expressed at high levels 
also in cells lacking p53, indicate that Wig-1 is not merely a target of the p53 tumor 
suppressor. Possibly, one or more of these transcription factors might regulated Wig-1 
expression in different conditions and maybe be tissue specific. 
Wig-1 promoter has been shown to be target for CpG methylation, and this modification is 
suggested to be the cause of Wig-1 downregulation in KM-H2 Hodgkin Lymphoma cells and 
in gastric cancer cell line infected by Epstein-Barr virus [24, 25]. 
Recent studies reveal that Wig-1 is also regulated epigenetically. ChIP-Seq analysis 
performed in mESC in two independent studies shows that Wig-1 is a target of the histone 
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methyl transferase PRC2 on H3K27me3 [26, 27]; indeed PCR2 silencing results in Wig-1 
upregulation [27]. A key function of PRC2 in mammals is to regulate stem cell function, 
where it can promote self-renewal through direct repression of pro-differentiation genes [28]. 
 
Table 2: List of transcription factor binding to Wig-1 promoter (ChIP-Seq data) 
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Interestingly, Wig-1 promoter in mouse embryonic stem cells (mESC) harbors both the 
activating H3K4me3 mark and the repressive H3K27me3 mark. These bivalent domains are 
considered to be a feature of developmentally regulated genes. They are maintained repressed 
until the time when a particular differentiation signal will switch the activating mark on and 
engage the cell to develop into a more specific functional type. Following differentiation, 
bivalent promoters embrace either an active or a repressed state, depending on cell fate. [26, 
29]. Remarkably, Wig-1 promoter in neural progenitor cells and embryonic fibroblasts carries 
H3K4me3 only [29]. Another study in mESC shows that Wig-1 has the classical methylation 
profile of genes expressed at high levels (positive H3K4me3, H3K36me3, and negative 
H3K27me3) [30]. 
PCR2 is also linked to pathogenesis of human cancer and it is commonly overexpressed or 
mutated in cancer [31]. Consistent with this notion, Wig-1 gene shows higher H3K27me3 
methylation in MLL-leukemia cell line as compared to 32D myeloblasts cells [27].  
Le Martelot et al. performed genome-wide analysis of the locations of RNA polymerase II 
(Pol II) and the epigenetic histone modifications H3K4me3 and H3K36me3 at specific times 
of the day, relating these data to mRNA expression levels. They show that Pol II 
transcriptional rhythms are biphasic in mouse liver, having predominant peak activities in the 
morning and evening. The analysis places Wig-1 among the class of core circadian clock 
genes, defined as genes whose protein products are necessary components for the generation 
and regulation of circadian rhythms. Wig-1 showed rhythmicity both in transcriptional and 
mRNA accumulation and its mRNA showed to be short-lived [32]. 
Altogether these evidences suggest a tight epigenetic regulation of Wig-1 expression. This 
regulation appears to be important for the modulation of Wig-1 function during development, 
differentiation and possibly carcinogenesis, but also, in the physiological regulation of 
circadian rhythms. 
 
1.5 POST-TRANSCRIPTIONAL WIG-1 REGULATION  
 
Not much is known about regulation of Wig-1 at mRNA level, although the presence of 
numerous regulatory motifs on it 3’UTR suggests that it might be target of a number of RNA-
binding proteins. As mentioned above (see also Figure 2) Wig-1 3’UTR contains both a type 
I and type II SECIS. SECIS elements are cis-acting stem-loop RNA structures that are found 
in the 3"-untranslated regions of all eukaryotic and archaeal selenoprotein mRNAs [33]. 
Interestingly, Wig-1 mRNA is bound by the eukaryotic initiation factor 4a3 (eIF4a3) as 
shown by HITS-CLIP analysis (Table 4) [34]. eIF4a3 acts as a transcript-specific repressor of 
selenoprotein mRNA translation during selenium deficiency [35]. Although no previous 
reports indicate Wig-1 as a potential non-essential selenoprotein, these data advise differently 
and it certainly deserves further investigation. Additionally, the Wig-1 3’UTR also contains a 
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GY-box (GUCUUCC) and the Brd-box (AGCUUUA) (Figure 2). These 7-nt motifs, found 
originally in Drosophila melanogaster, are known to mediate negative post-transcriptional 
regulation [36, 37]; they are broadly distributed in the 3" UTRs of Notch genes and function 
to constrain their activity during normal development of D. melanogaster nervous system. A 
study demonstrated that GY-box-containing 3" UTRs are inhibited by miR-7 and those with 
Brd-boxes by miR-4 and miR-79 [38]. miRNA-mediated regulation may be a conserved 
feature of Notch target genes in human according to [38], thus it is plausible and would be 
intriguing to investigate whether Wig-1 is also included in this scenario. RNA editing by 
adenosine deamination is a relatively common post-transcriptional alteration of mRNA 
catalyzed by the ADAR family of enzymes, which recognize the repetitive retrotransposable 
Alu element on the UTR of genes. Alu elements are also involved in the regulation of 
splicing [39, 40] and translation [41-43] of those transcripts that bear them, both positively 
and negatively. Wig-1 possesses two of these elements, namely an AluSx, a Alu subfamily 
that show the highest levels of editing [44] and an AluY, the evolutionarily youngest Alu 
subfamily in primates. Up to now, there are no reports showing usage of this motifs in Wig-1 
mRNA as target for RNA regulation or editing.  
 
Table 3: List of miRNAs that interact with mouse or human Wig-1 3’UTR 
 
In a study where Wig-1 mRNA was induced by p53 in HT29-tsp53 cells at 32°C (active p53), 
they showed that Wig-1 mRNA expression levels decreases at least eightfold within 6 h after 
the temperature shift to 38°C (inactive p53), indicating that Wig-1 mRNA half-life is lower 
that 2 h. This instability was found to correlate with the high content in AU-rich element of 
Wig-1 3’UTR (14 AUUUA pentamers and a 12 nts long T-stretch – Figure 2) [45]. Wig-1 
stability curve and 3’UTR composition was similar to those of the pro-arrest p21 gene, for 
which, regulation of stability on the 3’UTR by a number of RBPs has been reported [46, 47]. 
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These data also indicate that the transcriptional induction of short-lived mRNAs like Wig-1 is 
important to modulate the p53 response. Interestingly, other AU-rich binding proteins have 
been reported to bind to Wig-1 mRNA (Table 4), namely the stabilizing proteins hnRNP-C 
[48] and HuR [49] and the destabilizing protein FMRP [50] and TIAR [51].  
 
Table 4: List of RBPs associated to Wig-1 mRNA [34, 52, 54, 59, 64-74] 
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Next generation sequencing methods, particularly AGO proteins PAR- and HITS-CLIP, 
allowed to detect 24 miRNAs in human (in at least 5 out of 8 independent studies) [52-59] 
and 4 miRNAs in mouse (in at least 2 out of 3 independent studies) [60-62] as potential Wig-
1 mRNA targeting miRNAs (Table 3). Another study shows that miR-206 might be involved 
in the regulation of Wig-1 expression in glioblastoma cells (U373, GBM2, GBM5) [63]. 
Splicing might also affect Wig-1 expression and modulate it function in different context. It 
has been shown that Wig-1 alternative splicing is higher in neoplastic colonic epithelial cells 
than in healthy epithelial cells [75]. 
 
1.6 POST-TRANSLATIONAL WIG-1 REGULATION 
 
Wig-1 protein carries a number of post-translational modifications (PTMs) as shown by mass 
spectrometry data collected in our lab (Xu L. et al, Unpublished data). Figure 4 summarizes 
these findings. Interestingly, some sites differ in their phosphorylation status in unstressed as 
compared to stressed condition (cisplatin treatment), supporting the belief that Wig-1 plays a 
role in the cell response to stress and that PTMs might affect Wig-1 behavior in different 
conditions. Preliminary results from Co-IP experiments performed with phosphor- or 
acetylated antibody has confirmed part of the results found by MS analysis (Xu L. et al, 
Unpublished data). 
 
Figure 4: Wig-1 protein post-translational modifications identified by MS. Picture and data courtesy of 
Lidi Xu. 
  11 
1.7 WIG-1 IN PHYSIOLOGY AND DISEASE 
 
1.7.1 Wig-1 in cancer 
 
Human WIG-1 maps to 3q26.32 [8], a region that is commonly amplified in cancer and 
contains several genes with relevance to cancer, such as the phosphoinositide-3-kinase 
catalytic alpha polypeptide gene (PIK3CA) [76], the telomerase RNA component gene 
(TERC) [77, 78], the TP63 gene [79], and the sex-determining region Y-box 2 gene (SOX2) 
[80-82]. A recent study shows that Wig-1 is upregulated in 10 out of 10 tested cancers 
carrying wtp53 (breast carcinoma, colorectal cancer, glioblastoma, endometrial carcinoma, 
bladder carcinoma, ovarian serous adenocarcinoma, acute myelogenous leukaemia, lung 
adenocarcinoma, stomach adenocarcinoma and low-grade glioma) [83]. Contrarily, mutant 
p53 seems to exert a dominant negative effect over Wig-1 expression; indeed Wig-1 is 
expressed at lower levels in cells expressing mutant p53 (R273H, R249S, R175H and 
R280K) [84, 85]. In another investigation Wig-1 expression was tested in 82 melanoma 
metastases and found to be 6.7 fold lower compared to 8 melanocyte cell lines; in this case, 
the difference was not related to the p53 status of these tumors [86].  
 
 
Figure 5: Wig-1 alteration status in human cancers. Data issued from TCGA portal analyses. Only 
published results are shown in this graph. 
 
Through the visualization of the cancer genomic data stored in the cBioPortal for Cancer 
Genomics [87, 88], it is evident the level of Wig-1 alteration in different cancers. Figure 5 
shows Wig-1 status in: lung squamous cell carcinoma [89], head and neck squamous cell 
carcinoma, ovarian serous adenocarcinoma [90], prostate adenocarcinoma [91, 92], uterine 
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corpus endometrioid carcinoma [93], cancer cell line encyclopedia [94], breast invasive 
carcinoma [95], NCI-60 cell lines [96], lung adenocarcinoma [97], colorectal 
adenocarcinoma [98], glioblastoma [99], bladder urothelial carcinoma [100, 101], kidney 
renal clear cell carcinoma [102], melanoma [103], esophageal adenocarcinoma [104]. Figure 
5 reveals that Wig-1 is mostly amplified and very rarely deleted.  
Despite these data, a study focused on the analysis of Wig-1 expression in cervical carcinoma 
cell lines and patient tumor biopsies (squamous cervical carcinomas and adenocarcinomas) 
revealed that Wig-1 is not the critical gene that drives 3q gain in cervical cancer [105]. This 
indicates that additional studies are necessary in order to evaluate how relevant is Wig-1 
amplification for tumor formation and/or progression. Nevertheless, considering that Wig-1 is 
required in order to maintain cell proliferation, it is plausible to think that the tumor might 
benefit from its increased expression somehow. 
Figure 6 shows the location and type of mutations found on Wig-1 gene in the cancers tested 
in Figure 5. Similarly to what previously discussed about the relevance of Wig-1 
amplification, further investigation is needed in order to determine whether these alterations 
are passenger (i.e. a random and natural consequence of cancer's elevated mutation rate) or 
driver (i.e. cancer-causing) mutations. 
 
 
Figure 6: Wig-1 gene mutations found in human cancers. Data issued from TCGA portal analyses. 
 
1.7.2 Wig-1 in stem cell maintenance and differentiation 
 
Wig-1 is expressed at higher levels in haematopoietic, neuronal and embryonic stem cells 
compared to the corresponding differentiated cell types [106]. Depletion of Bmi-1, a factor 
required for maintenance of adult self-renewing haematopoietic stem cells, led to 
upregulation of Wig-1 in these cells [107]. These data suggest a role of Wig-1 in stem cell 
maintenance. Besides, the fact that Wig-1 mRNA is upregulated (84 fold change) by the 
nerve growth factor (NGF), a neurotrophin essential for neuronal differentiation, indicates 
that it might also play a role in cell differentiation [108]. Additionally, Wig-1 promoter in 
mouse embryonic stem cells harbors both the activating H3K4me3 mark and the repressive 
H3K27me3 mark. These bivalent domains are believed to control the expression of 
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developmental genes, maintaining repression in the absence of differentiation signals [26, 
29]. Table 2 shows a list of TFs that bind to Wig-1 promoter. Among them, SPI1, a factor 
with a distinctive and indispensable role in maintenance of hematopoietic stem cells and their 
differentiation [109]. Moreover, ETS1 and ELF1 has been identified as potent TF for ESC 
differentiation toward blood cells [110]. MAX has been recently proposed as repressor of 
germ cell-related genes in embryonic stem cells [111]. Last but not least, p53, confirmed 
Wig-1 activator, has been extensively reviewed for its role in embryonic, adult and induced 
pluripotent stem cell regulation [112-115]. Unpublished results from Vilborg et al., shows 
that homozygous Wig-1 mice knockout is associated with lethality before the blastocyst stage 
thus emphasizing the possibility that it has indeed a determining role in stem cell 
maintenance and differentiation [12]. 
 
1.7.3 Wig-1 in the brain 
 
A number of studies indicate that Wig-1 has a role in the physiology of the brain, as its 
deregulation is associated with different neurological disorders. Wig-1 is abundantly 
expressed in the central nervous system [5] and its expression increases in the hippocampus 
following transient cerebral ischemia [116-119]. The rat Wig-1 homologous, PAG608, is 
induced in motor neurons of L-DOPA-injected hemi-parkinsonian rats [120]. Its expression is 
also increased in lumbar spinal cord motor neurons of transgenic mouse model of 
amyotrophic lateral sclerosis (ALS) [121] and it has been proposed as a marker for ALS 
onset. Moreover, Wig-1 is among the genes that are downregulated in VEGF-/- mice at the 
age of five month, the time when these mice develop a motor neurodegenerative phenotype 
that resemble ALS [122]. Additionally, PC12 cells (neural crest origin) treated with NGF, a 
neurotrophin essential for neuronal differentiation, lead to increase in Wig-1 gene expression 
by eighty-four fold change [108]. Sedaghat et al, performed a microarray analysis in mouse 
brain after Wig-1 knockdown using highly specific antisense oligonucleotides (ASOs) and 
found a 50% significant reduction in mutant huntingtin protein, but also proteins such as the 
autism susceptibility candidate 2 (AUTS2), linked to neuropathy of autism, the roundabout 
axon guidance receptor homolog 2 (ROBO2), critically important for axon guidance and in 
CNS development, the inner mitochondrial membrane peptidase 2-like (IMMP2L), a 
mitochondrial peptidase that has been linked with Autism Spectrum Disorders (ASDs) and 
with Tourette Syndrome [123]. ChIP-Seq analysis revealed that Wig-1 is one of the target of 
the nuclear respiratory factor 1 (NRF1), a TF whose deregulation contributes to 
neurodegenerative processes underlying Parkinson’s, Alzheimer’s and Huntington’s disease 
[124]. Also, a protein arrays used for the identification of Tau/#-amyloid protein interactors 
on large scale (main constituent of amyloid plaque in the brains of Alzheimer’s patients) 
indicated Wig-1 has one of the partners [18]. 
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1.8 THE p53 TUMOR SUPPRESSOR 
 
The p53 protein (also known as tumor protein 53, TP53) is a nuclear transcription factor [125, 
126] and one of the most important tumor suppressors, as proved by the fact that the 
inactivation of the p53 network is required for the development of nearly all human cancers 
(http://p53.fr) [127]. The transcriptional activity of p53 is crucial for its tumor prevention and 
suppression function [128]. p53 binds DNA in a sequence specific manner (Figure 1 shows 
p53 response element (RE)) [129]. A transcription-independent induction of apoptosis by p53 
has been reported [130-132], however the tumor suppression function of p53 is primarily due 
to its role as a transcription factor (Figure 7). 
Up to now, as many as 45,000 p53 somatic gene mutations have been reported [127], 
designating p53 as the most frequently mutated gene in human tumors. Moreover, a germline 
mutations of p53 in Li-Fraumeni syndrome patients, characterized by very high cancer 
susceptibility, provided a straight link between tumor development and p53 mutation [133]. 
These observations demonstrate the critical role of p53 in tumor prevention. In addition to 
p53 gene mutations, other mechanisms such as viral infection or alterations of key regulators 
of p53 activity can also lead to its inactivation. For example, certain DNA viruses (e.g. SV40, 
HPV and adenoviruses) encode proteins that bind and target p53 for degradation [134]. 
Additionally, MDM2 and MDM4, two negative regulators of p53, are amplified in a variety 
of cancers [135], while the p53 upstream positive regulator ARF/p14ARF gene can be deleted 
or epigenetically inactivated [136]. 
In unstressed cells, p53 protein is maintained at very low levels by Mdm2, an E3 ubiquitin 
ligase that promotes p53 degradation; the Mdm2 gene is positively regulated by p53, defining 
a negative feedback loop that controls p53 activity. Cellular stress releases the inhibitory 
effects of Mdm2, thus triggering p53 stabilization and activation. Once activated, p53 exerts 
its protective function by repairing damaged DNA and inhibiting the proliferation of 
potentially tumorigenic cells through induction of cell cycle arrest, senescence or apoptosis 
(Figure 7) [137]. The p53 response is elicited by a variety of stress signals such as DNA 
damage, oncogene activation, abnormal mitosis, loss of cell–cell contact, nutrient deprivation, 
telomerase shortening and hypoxia [137]. p53 is a powerful transcriptional regulator able to 
regulate the expression of hundreds of genes [137, 138]. To add more complexity, p53 
interacts with several cofactors and binding partners affecting its transcriptional activity. 
Moreover, the other p53 family members, p63 and p73, can also modulate transcription and 
share a number of target genes with p53 [139-142]. 
Three major post-translational modifications (ubiquitination, phosphorylation and 
acetylation) are responsible for regulating the activity and stability of p53 [143-145] and 
altogether affect the precise and selective behavior of p53.  
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Figure 7: Schematic representation of p53 functions 
 
1.8.1 p53 and cell fate decision 
 
Understanding the molecular basis of p53 selectivity among its distinct transcriptional targets 
is crucial in the comprehension of how p53 chooses between life or death for the cell. The 
ability of p53 to display a varied range of responses to stress and what factors are modulating 
the choice have been investigated for some time. p53 is a cellular stress sensor; in response to 
mild reparable damage, p53 triggers transient cell cycle arrest allowing the necessary time for 
repair of the damage and cell cycle re-entry. Differently, severe or irreparable DNA damage 
will often lead to apoptosis (Figure 7) [146]. It is known that promoter-selective 
transactivation of p53 targets is crucial for the diverse cellular responses to distinct stresses. 
p53 transcription selection depends on several mechanisms such as post-translational 
modification of p53, interaction with different binding partners and gene specific chromatin 
modification. For example, DNA damage induces p53 phosphorylaytion at serine 46 by 
several kinases such as HIPK2, DYRK2 and p38 [147-149]. This modification turns p53 into 
a conformation that is more efficient at transactivating the expression of the proapoptotic 
target genes p53AIP1, Noxa, Perp, and PUMA [150, 151], while there is no effect on the 
expression of the pro-arrest gene p21. Similarly, acetylation of lysine 120 after DNA damage 
by the MYST family of acetyl transferases augments the pro-apoptotic function of p53 [152, 
153]. Both acetylation and ubiquitylation at lysine 320 have been reported and they can 
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trigger apoptosis or growth arrest, respectively [154]. The ASPP family of proteins (apoptosis 
stimulating protein of p53) can bind and regulate the activities of p53 [155]. Chromatin 
immunoprecipitation (ChIP) assays revealed that binding of ASPP1 and ASPP2 to p53 can 
promote p53 interaction to promoters of pro-apoptotic genes, such as Bax and PIG3, but not 
to the cell cycle arrest gene CDKN1A or MDM2. Contrarily, iASSP binds p53 and inhibits 
p53-mediated apoptosis [156, 157]. Other proteins that are involved in the modulation of p53 
target selectivity are the Brn3 family of POU domain transcription factors [158], the YB1 
protein [159], and Hzf (hematopoietic zinc finger), a potent pro-survival regulator of p53 
transactivation [160, 161]. The cellular apoptosis susceptibility gene hCAS/CSE1L plays a 
role in p53 promoter selection by enhancing the transcription of pro-apototic genes through 
gene-specific chromatin modifications. hCAS/CSE1L associates with PIG3 and p53AIP1 
promoters (but not p21) and decreases H3K27me3 thus enhancing their transcription [162]. 
 
1.8.2 Regulation of p53 at RNA level 
 
p53 mRNA is targeted for both translational and stability regulation by a variety of RNA-
binding protein. For instance, PTB, hnRNPC1/C2, MDM2, RPL26, DAP5, Annexin A2, 
HuR and PSF bind to p53 mRNA and positively regulate its translation [163-169], while 
Pdcd4, RNPC1 and nucleolin negatively regulate p53 mRNA translation [166, 170, 171]. p53 
protein itself can bind to its own 5"-UTR and inhibit its translation [172]. HuR protein can 
also bind to p53 3’UTR and increases p53 mRNA stability [173]. Another mechanism of 
3"UTR mediated p53 regulation is through microRNAs. miR-125b, miR-504, miR-25, and 
miR-30d directly target the 3"UTR of p53 mRNA and down-regulate p53 protein levels, 
which results in reduced expression of genes that are transcriptionally activated by p53 [174].  
 
1.9 THE N-MYC ONCOGENE 
 
N-Myc is a transcription factor and a member of the MYC family of proto-oncogenes [175]. 
N-Myc regulates the expression of genes involved in proliferation, growth, apoptosis, energy 
metabolism, and differentiation and plays an essential role in normal brain development. N-
Myc is expressed primarily in nervous tissues early during embryonic development, and is 
absent in most adult tissues. Amplification of N-Myc occurs in 20–22% neuroblastomas at 
diagnosis and 40% progressive neuroblastomas, an embryonic tumor derived from primitive 
cells of the sympathetic nervous system [176, 177]. N-Myc amplification has also been 
reported in retinoblastoma [178] and small cell lung carcinoma [179]. N-MYC amplification 
results in increased levels of cellular proliferation, decreased apoptosis, lack of cell 
differentiation and enhanced tumor vascularization [180]. Malignant neuroblastoma is one of 
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the most common and deadly solid tumor in infants and children and N-Myc amplification is 
the single most predictive factor for bad prognosis in this disease [181]. N-Myc knockdown 
by siRNA in neuroblastoma cells carrying N-Myc amplification can induce differentiation 
[182], and antisense strategies that target N-Myc inhibit mouse neuroblastoma tumorigenesis 
in vivo [183].  
 
1.10 FAS 
 
FAS (also referred as Apo1/CD95 receptor) is a member of the tumor necrosis factor (TNF) 
receptor family of transmembrane receptors. FAS receptor is expressed in almost all tissues, 
while its ligand FASL expression is restricted to activated lymphocytes and immune-
privileged sites such as lung, brain, testis and eye [184]. In these immune-privileged sites, the 
expression of FASL leads to apoptosis and immunosuppression, providing protection from 
destructive inflammatory responses [185]. Binding of FASL to FAS receptor triggers 
recruitment of specific adaptor proteins, activation of caspase cascades and induction of 
apoptosis [186]. The recognition of FASL by FAS induces FAS trimerization and interaction 
of the adaptor FAS-associated death domain-containing protein (FADD) to the intracellular 
FAS death domain (DD). This in turn leads to recruitment, dimerization and activation of 
caspase-8 [187, 188]. Activated caspase-8 induces apoptosis either through direct cleavage 
and activation of caspase-3 [189], or through cleavage of Bid, a pro-apoptotic Bcl-2 family 
protein. Truncated Bid (tBid) translocates to mitochondria, inducing cytochrome c release, 
which sequentially activates caspase-9 and -3 [190]. 
FAS receptor gene is located on chromosome 10 in human cells and seven distinct protein 
isoforms have been identified and arise from alternative splicing of FAS receptor RNA. Only 
isoform 1 encodes the functional, full-length protein of 335 amino acids. It contains three 
cysteine-rich pseudo-repeats, a transmembrane domain and an intracellular death domain. 
Isoforms 2, 4, 5, 6 and 7 lack the transmembrane domain and are therefore soluble isoforms 
who are thought to sequester and inactivate FAS ligand thus antagonizing FAS-receptor-
mediated apoptosis [191]. Isoform 3 does not contain a functional intracellular death domain, 
and it might be involved in resistance of fetal thymocytes to apoptosis following FAS 
receptor aggregation [192]. The soluble anti-apoptotic FAS isoforms are generated by 
skipping of exon 6 [193]. A number of splicing regulators have been found to influence this 
splicing event including PTB, TIA1, HuR, hnRNPC, EWS and RBM5 [194-200].  
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1.11 POST-TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION 
 
Regulation of gene expression is a fundamental process through which mammalian cells 
regulate cell survival, adaptation to stress, homeostasis, cell fate and differentiation, in 
response to different stimuli and environmental signals [201]. Newly transcribed mRNAs are 
subjected to posttranscriptional events that dictate the levels of the encoded proteins. These 
events comprise mRNA processing, nucleo-cytoplasmic export, mRNA localization, mRNA 
stabilization and translational regulation. All these processes involve the binding of proteins 
(trans-acting factors) to regulatory sequences on coding or untranslated regions of mRNAs 
(cis-acting elements). There are several types of cis-acting elements that affect the fate of the 
mRNA and they can be distributed throughout the transcript sequence. 
The 5" UTRs can contain:  
- upstream open reading frame (uORF), it can affect the efficiency of translation 
initiation of the main downstream ORF or trigger mRNA decay [202];  
- internal ribosome entry site (IREs), it promotes translation initiation independently of 
the presence of the commonly utilized 5'-7mG cap [203];  
- iron responsive element (IRE), secondary stem-loop structure of 26–30 nucleotides 
found in the mRNA of proteins involved in iron metabolism, it regulates their 
translation or stability [204];  
- 5" terminal oligopyrimidine tract (5"TOP), it contains a cytidine residue at the cap site 
followed by a stretch of up to 13 pyrimidines and it is critical for translational control 
all of which are known to be involved in translation regulation [205]; 
- polypyrimidine tract, a 15-20 base pairs long pyrimidine rich region located about 5-
40 base pairs before the 3' end of introns, it affects early stages of the splicing process 
[206]; 
- miRNAs, small noncoding RNAs that promotes degradation or translation repression 
of the target mRNA through sequence complementarity [207, 208]. 
On the coding region: 
- the coding region determinant (CRD), a non-sequence specific element, about 80-90 
nt long, that affects both mRNA stability and translation [209, 210];  
- miRNAs, see above [211-213]. 
The 3" UTRs contain cis elements such as: 
- zipcode sequences, highly variable in length, structure and complexity, they can 
regulate mRNA localization, anchorage and translation [214, 215]; 
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- AU-rich elements (ARE), see following paragraph [216]; 
- GU-rich element (GRE), a highly conserved sequence (UGU[G/U]UGU[G/U]UGU) 
that targets mRNA for rapid deadenylation and degradation [217, 218]; 
- CA-rich elements (CAREs), CA-dinucleotide repeats exerting stabilization effects on 
mRNA [219]; 
- miRNAs, see above [220]; 
- poly(A) signals (PASs), consensus AAUAAA sequences located about 10-35 
nucleotides upstream of the actual site of poly(A) tail addition [221, 222].  
 
The length of the 3" UTR is determined by the maturation process of the 3" end of the pre-
mRNA, which results in cleavage and polyadenylation of the mRNA. Alternative 
polyadenylation in the 3"UTR generates different mRNA isoforms containing distinctive cis-
acting elements, thus conferring different stabilities and/or translation properties to the 
corresponding mRNAs [223]. 
 
1.11.1 AU-rich elements 
 
Described for the first time in 1986 in the 3’-UTR of unstable mRNAs coding for cytokines 
[224], adenylate/uridylate-rich elements (AU!rich elements or AREs) are now the most well 
studied group of cis-acting elements. AREs are found in the 3’UTR of short-lived mRNAs, 
typically proto-oncogene and inflammatory mediators, and are important in controlling 
mRNA stability and translation. The basic core of the canonical ARE consists of an AUUUA 
pentamer embedded in an AU-rich context. Based on the number and the distribution of 
AUUUA pentamers, AREs have been divided into three classes [216, 225]. Class I AREs are 
characterized by several scattered AUUUA motif within U-rich regions (e.g. AREs found in 
c-myc and c-fos). Class II AREs contain at least 2 or more overlapping 
UUAUUUA(U/A)(U/A) nonamers (e.g. AREs found in TNF alpha and VEGF). Class III 
AREs are much less well defined, they lack the AUUUA motif but contain a U-rich regions 
(e.g. AREs found in c-jun and p53). Bioinformatics evaluations estimate that 5–8% of human 
genes contain ARE sequences [226]. 
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1.11.2 AU-rich element binding proteins 
 
AU-rich elements are bound by a set of RNA-binding factors collectively called ARE-
binding proteins (ARE-BPs). Over twenty ARE-BPs have been identified until now [227, 
228] and their RNA-binding domains include RNA Recognition Motifs (RRMs), zinc fingers 
and K homology (KH)-domains. Some ARE-BPs can promote mRNA degradation, for 
example tristetraprolin (TTP) [229, 230], butyrate-regulated factor-1 (BRF1) [230] and KH 
domain-splicing regulatory protein (KSRP) [231]; others work as mRNA stabilizers, for 
example human antigen R (HuR) [232] and the poly(A)-binding protein-interacting protein 2 
(PAIP2) [233]; some can do both, for example AUF1/hnRNP D [228]. Yet another subset of 
ARE-BPs represses translation of their mRNA targets, for example the T-cell intracellular 
antigen 1 (TIA-1) and TIA-1-related protein (TIAR) [234]. Both cooperation and antagonism 
between different ARE-BPs has been observed in regulation of mRNA expression of a 
common target [235, 236]. Furthermore, subcellular localization of the targeted transcript 
and/or post-translational modifications of ARE-BPs are also important factors that determine 
the final outcome of the regulation [237, 238]. 
 
1.11.3 AU-rich element mediated mRNA decay (AMD) 
 
The mRNA levels inside a cell depend on the balance between transcription and degradation 
rates. Transcripts that contain AREs are particularly susceptible to mRNA decay through a 
process known as ARE-mediated decay (AMD) [239]. AMD can promote mRNA 
degradation by three major pathways: 1) shortening of the poly-A tail (deadenylation) 
followed by 3’-to-5’ mRNA degradation via the exosome; 2) deadenylation followed by 
removal of the 5" cap (decapping) and 5’-to-3’ mRNA decay; 3) miRNA-mediated 
endoribonucleolytic cleavage. Most ARE-BPs are not the direct executors of AMD, instead 
they recruit and regulate enzymes of the RNA degradation machinery.  
Deadenylation is the first and often rate-limiting step in the regulated mRNA decay 
pathways. Two cytoplasmic deadenylase complexes (Pan2/Pan3) contribute to the reduction 
in poly(A) tails, followed by a large complex of exoribonucleases and adaptor proteins 
termed the Ccr4–Not complex that hydrolyze the poly(A) tail progressively reducing its 
length to 10-15 As. After deadenylation, the unprotected 3"-end of the mRNA is degraded by 
the exosome, a protein complex (10-12 subunits) consisting of 3"-to-5" exo- and 
endoribonucleases [240].  
Deadenylation also triggers 5"-to-3" RNA decay, starting from the removal of the 5"-m7G-cap 
by the Dcp1/Dcp2 decapping complex [241] and followed by 5"-to-3" degradation promoted 
by the cytoplasmic exonuclease Xrn1 [242, 243]. Decapping of the 5"- m7G -cap structure is a 
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prerequisite for 5"–3" decay since Xrn1 has less than 1% relative activity on capped RNAs 
[244].  
The third AMD decay pathway involves the mediation of microRNA. MicroRNAs 
(miRNAs) are short RNA molecules (20-22 nts) involved in post-transcriptional gene 
regulation. miRNAs associate with a protein complex termed the RNA-induced silencing 
complex (RISC). The RISC complex can target RNAs that show complementarity to the 
miRNA, leading to site-specific endonuclease cleavage by Ago2 (a component of the RISC) 
and degradation of the resulting target RNA by Xrn1 and the exosome. miRNAs can bind to 
AREs and enhance or inhibit the action of ARE-BPs to regulate ARE bearing transcripts 
[239, 245-248]. However, a recent study showed that AMD can function independently of 
miRNAs in mouse and Drosophila cells [249]. 
Cytoplasmic mRNA localization can also be affected by the presence of AU-rich elements on 
their 3’UTRs. Processing bodies (P-bodies or PBs) are distinct cytoplasmic granules that 
contain components of the mRNA degradation machinery necessary for 5’-to-3’ mRNA 
decay [250]. Decay promoting ARE-BPs, such as TTP and BRF-1/2, are found in P-bodies, 
suggesting that they may recruit ARE-containing mRNAs to P-bodies for degradation [251]. 
Differently, stress granules (SGs) are a separate type of cytoplasmic granule that can be 
induced upon cellular stress. Transcripts in SGs are subjected to mRNA triage and, 
depending on the duration and severity of the stress, re-routed to sites of translation 
reinitiation, storage, or to P-bodies for decay [252]. The ARE-BPs TIA-1, TIAR, and TTP 
among others, are components of stress granules and recruit their target transcripts to stress 
granules in an ARE-dependent manner. A comprehensive review by von Roretz et al. 
discusses the regulation of ARE-containing mRNAs by ARE-BPs in response to stress, along 
with the involvement of cytoplasmic granules [253]. 
 
1.11.4 Importance of RNA 2D and 3D structure 
 
RNA is a polymer composed by the combination of the A, U, C and G ribonucleotides. RNA 
is a single-stranded molecule and complementary sections within a single strand of RNA can 
base-pair with each other, causing the molecule to fold itself and form a complex, three-
dimensional shape. RNA can form A–U and G–C base pairing, just like DNA, but the non-
Watson–Crick G–U wobble pair is also commonly observed and has approximately the same 
stability as an A–U [254]. RNA 2D and 3D architectures are critical for many aspects of 
cellular physiology such as RNA transcription, splicing, translation, localization and turnover 
[255-259]. Moreover, RNA molecules not only carry the DNA-encoded information from the 
nucleus to the cytoplasm, but they also catalyze biochemical reactions as exemplified by 
ribozymes [260]. Unlike DNA binding proteins, which typically recognize features in the 
major groove of double-stranded DNA, RNA binding proteins, through their RNA binding 
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domain, recognize single-stranded RNA, double-stranded RNA, 3D structural features of 
folded RNAs or they may bind RNA non-specifically [261].  
In the last few decades, RNA structure prediction has been the focus of much research aiming 
at developing tools and computational methodologies for the analysis of RNA sequences. The 
aim is to identify different RNA secondary and tertiary structures, understand their biological 
functions and how these structures can affect protein/RNA interactions. RNA bioinformatics 
provides tools for folding of single and multiple RNA sequences, thus contributing in the 
description of RNA–RNA interactions as well as RNA–protein interactions.  
The most commonly applied 2D structure prediction methods rely on folding 
thermodynamics [262], but there are complementary approaches that use, for example, 
kinetics or probabilistic models [263, 264]. 3D structure prediction is a developing frontier in 
RNA biology. While there are a number of algorithms able to predict correct 3D structure of 
smaller RNA molecules, the problems appear with the prediction of known complex 
structures, thus, the question whether these tools are accurate and reliable for the prediction of 
new structures. Available methods for RNA 3D structure prediction and experimental 
techniques that provide RNA structural information are reviewed in [265]. 
 
1.12 PROTEIN-RNA INTERACTION ANALYSIS AND HIGH-THROUGHPUT 
TECHNIQUES  
 
Identification of RNA–protein interactions rely on the combination of both experimental and 
computational methods. Experimental methods include RNA co-immunoprecipitation from 
cell or tissue extracts to determine RNA targets (RIP). In the earlier approaches bound RNA 
was identified using microarrays (RIP-chip) [266] or more recently by RNA sequencing 
(RIP-Seq) [267]. However, RIP–chip and RIP-Seq capture only the relatively stable protein–
RNA complexes, requiring the application of complementary methods to detect the more 
transient interactions. UV cross-linking and immunoprecipitation and sequencing (CLIP-Seq) 
was then developed (also called HITS-CLIP for High-throughput sequencing of RNA 
isolated by cross-linking and immunoprecipitation) [268]. CLIP exploits the photoreactivity 
of pyrimidines and specific amino acids to create covalent crosslinks between RNA binding 
proteins and their interacting RNAs and allows to identify the site of the interaction at a good 
resolution. Interestingly, HITS-CLIP was also applied to Argonaute (Ago)/miRNA 
complexes, providing a molecular view on miRNA–mRNA interactions [269]. Another 
variant includes PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation), which differs from CLIP as it features the incorporation of the 4-
thiouridine (4-SU) and 6-thioguanosine (6-SG) photoreactive nucleotide analogs into RNA 
during transcription [270]. This modification increases the efficiency of the UV crosslinking 
and the accuracy in mapping the binding site. An additional improvement is represented by 
iCLIP (individual-nucleotide resolution CLIP), where efficiency of CLIP is further optimized 
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thanks to a different cDNA cloning protocol and circularization of the reverse transcription 
products, which enables identification of the cDNAs that truncate at the cross-link sites [271]. 
An extensive review by Milek et al. gathers novel applications of high-throughput sequencing 
to study protein–RNA interactions [272]. 
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2 AIM OF THIS THESIS 
 
The overall aim of this thesis was to characterize the Wig-1 protein function and to identify 
its associated RNA targets. Moreover, we aimed to investigate the biological implication of 
the regulation of some of these targets. 
The specific aims of each paper were: 
Paper I: To study the mechanism of Wig-1-mediated regulation of p53 mRNA. 
Paper II: To study the mechanism of Wig-1-mediated regulation of N-Myc mRNA and the 
implication in neuroblastoma cancer cells differentiation. 
Paper III: To study the effects of Wig-1 knockdown on global gene expression and cell 
survival with focus on the mechanism of Wig-1-mediated regulation of the pro-apoptotic 
FAS at the RNA level. 
Paper IV: To characterize the RNA-binding properties of Wig-1 and identify the Wig-1 
interacting transcriptome. 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
 
The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element 
Wig-1 is a p53 transcriptional target and with the intent to elucidate Wig-1 biological 
function we were intrigued by the observation that Wig-1 knockdown using siRNA led to 
decreased p53 protein levels. We were then able to confirm that Wig-1 silencing causes p53 
protein levels reduction both in unstressed cells and after p53 activation with the DNA-
damaging drugs. Additionally, overexpression of exogenous Wig-1 not targetable by siRNA 
rescued p53 levels, demonstrating that the decrease on p53 levels is a consequence of 
endogenous Wig-1 loss. Moreover, we could show that Wig-1 had a positive role in the p53 
response to cellular stress. 
Wig-1 is an RNA-binding protein [15, 16] and our lab have previously described the 
interaction between Wig-1 protein and two RNA-binding proteins involved in all aspects of 
RNA regulation, i.e. RHA and hnRNPA2/B1 [17]. We therefore asked if Wig-1 was 
regulating p53 RNA levels as well. This was indeed the case, in fact, we showed that absence 
of Wig-1 led to increased p53 mRNA decay and increased p53 mRNA deadenylation. 
Localization studies indicated that Wig-1 protein is present in both nucleus and cytoplasm, 
and more importantly it was found to be able to shuttle from nucleus to cytoplasm, the 
compartment where mRNA decay takes place [238, 256]. 
In order to understand which region in p53 mRNA was responsible for the regulation, we 
tested different deletion constructs of the p53 transcript. Through GUS reported assay we 
verified that the U-rich region in p53 3’UTR is responsible for Wig-1-mediated regulation of 
p53. The same region was also found to be crucial for Wig-1 binding to p53 mRNA as 
assessed by biotin pulldown assay. Moreover, we confirmed binding of Wig-1 to endogenous 
p53 mRNA by RNA immunoprecipitation assay. 
In summary, the main findings of this paper are: 
• Wig-1 binds and stabilized p53 mRNA through a U-rich element on p53 3’UTR 
• Wig-1-p53 positive feedback loop is important for maintaining the basal p53 mRNA 
levels and to augment the p53 response to cellular stress.  
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3.2 PAPER II 
 
Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth 
 
In paper I we published that Wig-1 binds and regulates p53 mRNA through a U-rich element 
on the 3’UTR. U-rich elements belong to the family of AU-rich elements (ARE). Thanks to 
this finding we could place Wig-1 in the group of the AU-rich element binding proteins 
(ARE-BPs). Many well-studied ARE-BPs can regulate a number of different targets [228]. In 
order to find novel Wig-1 regulated transcripts, we knocked down Wig-1 and tested the levels 
of a number of proteins whose mRNA was previously reported to be targeted by ARE-BPs. 
N-Myc protein, whose mRNA has been previously reported to be stabilized by the ARE-BP 
HuD [273, 274], was included in the screen and found to be dramatically reduced in the 
neuroblastoma cell line SK-N-BE(2) after Wig-1 silencing. This discovery set the stage for 
what became paper II. 
We started by confirming our preliminary data by knocking down Wig-1 in two 
neuroblastoma cell lines carrying N-Myc amplification, SK-N-BE(2) and Kelly. We detected 
a significant reduction in both N-Myc protein and mRNA levels. We next investigated what 
region in N-Myc mRNA is required for Wig-1-mediated regulation. Looking at N-Myc 
3’UTR we identified a U-rich element and a general AU-rich region containing two canonical 
AREs (referred as proximal and distal ARE). We generated different deletion constructs that 
we tested through a luciferase reporter assay and a pulldown assay and we found that the 
proximal ARE was determining factor for the binding and the regulation.  
We then wanted to investigate if Wig-1 mediated regulation of N-Myc mRNA had any 
relevant biological consequences in neuroblastoma cells. It has been previously reported that 
N-Myc knockdown causes differentiation in SK-N-BE(2) cells carrying amplified N-Myc 
[182]. We knocked down Wig-1 in these cells and looked for differentiation marker and 
changes in morphology. We recorded substantial morphological changes, increased cell cycle 
arrest in G1 phase and upregulation of the differentiation marker Neuropeptide Y (NPY) 
already 4 days after Wig-1 silencing, suggesting that inhibition of N-Myc expression resulted 
in differentiation. Overexpression of exogenous N-Myc lacking the 3’UTR (thus lacking the 
region responsible for Wig-1 mediated regulation) could rescue cells from undergoing 
differentiation, proving that the differentiated phenotype observed after Wig-1 knockdown is 
a direct consequence of Wig-1 effect on N-Myc mRNA. Furthermore, as we could not detect 
any signs for differentiation after Wig-1 knockdown in SH-SY5Y neuroblastoma cells that do 
not carry amplified N-Myc, we conclude that the effect of Wig-1 knockdown on 
differentiation of cells carrying amplified N-Myc is due to attenuated N-Myc expression. 
We next investigated if Wig-1 knockdown had any impact on tumor formation in vivo. We 
inoculated SK-N-BE(2) cells pre-transfected with siRNA against Wig-1 or control siRNA 
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subcutaneously in nude mice. Tumor take in the xenograft model was delayed in SK-N-
BE(2) cells pre-transfected with siRNA targeting Wig-1 (with a mean of 24 days) compared 
with control siRNA (with a mean of 19.5 days). Thus, transient Wig-1 knockdown is 
sufficient to significantly delay development of N-Myc-driven tumors in nude mice. 
The findings included in this study suggest that the design and the development of a 
therapeutic strategy to target either Wig-1 expression or Wig-1 protein/N-Myc mRNA 
interaction could be an alternative or an improvement to current therapeutic strategies in the 
treatment of aggressive and recurrent neuroblastoma carrying amplified N-Myc, which is the 
most deadly cancers in children [275]. 
Moreover, we also showed that treatment of IMR-32 neuroblastoma cells, which carry wild-
type p53, with chemotherapeutic drug led to activation of p53 and increased levels of both 
Wig-1 and N-Myc protein. This suggests the idea of a p53-Wig-1-N-Myc axis that is 
activated upon stress. According to this model, activated p53 will induce cell cycle arrest 
genes and Wig-1; Wig-1 will then stabilize N-Myc and promote the recovery and cell 
survival after p53-induced cell cycle arrest in response to stress. Meanwhile, Wig-1-mediated 
stabilization of p53 mRNA will guarantee basal levels of p53 and prompt action in case of 
persistent stress. 
To summarize, the main findings of this paper are: 
• Wig-1 as a novel regulator of N-Myc mRNA.  
• Wig-1 binds and stabilizes N-Myc mRNA through an ARE-containing region in the 
N-Myc 3’UTR. 
• Loss of Wig-1 in SK-N-BE(2) neuroblastoma cells carrying amplified N-Myc triggers 
cell differentiation as a consequence of Wig-1-mediated regulation of N-Myc mRNA.  
• Wig-1 knockdown is sufficient to significantly delay development of N-Myc-driven 
tumors in mice. 
 
3.3 PAPER III 
 
Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3! 
Papers I and II describe Wig-1-mediated regulation of the tumor suppressor p53 and the N-
Myc oncogene at RNA level through two distinct AU-rich elements in their 3’UTR. Wig-1 is 
undeniably involved in post-transcriptional gene regulation and to gain an overall picture of 
the effect of Wig-1 on global gene expression we decided to perform microarray analysis 
after Wig-1 knockdown in the HCT116 colon carcinoma cell line. Loss of Wig-1 led to 
deregulation by more than four-fold of 2447 transcripts that are involved in pathways such as 
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Alzheimer’s and Huntington’s diseases, p53 pathway, FAS signaling pathway and apoptosis. 
We showed in Paper I that the p53 target Wig-1 is a regulator of p53 mRNA, thus it wasn’t 
surprising to find the p53 pathway and the apoptosis pathway among most significantly 
affected pathways. We then moved on to validate our microarray data; six out of eight of the 
targets chosen for validation were confirmed at protein level (i.e. FAS, WNT1, AKT3, APP, 
14-3-3! and PPP2CB). We found that Wig-1 silencing led to increase levels of the 
proapoptotic factor FAS and reduced levels of the cell cycle arrest associated factor 14-3-3!, 
suggesting that Wig-1 can modulate the cellular stress response such that cell cycle arrest is 
favored over apoptosis. Through FACS-PI analysis and apoptotic assays, we confirmed that 
Wig-1 silencing enhanced apoptosis and reduced cell cycle arrest in response to cellular stress 
in HCT116 cells. Notably, our data demonstrated that Wig-1 regulates FAS and 14-3-3! 
independently of p53, as evidenced by the comparable effect in both p53 wt and null HCT116 
cells with and without stress. We suggested that Wig-1 acts to maintain high levels of 14-3-
3! (thus promoting cell cycle arrest) while at the same time inhibiting FAS (and thus, 
repressing apoptosis), the net outcome being increased survival.  
We found that Wig-1 binds to the ARE in the 3’-UTR of FAS mRNA and that the binding is 
mediated by the first zinc-finger in Wig-1. Moreover, this ARE is responsible for Wig-1-
mediated regulation of FAS mRNA and its removal completely abrogates binding and 
regulation.  
We found that Wig-1 co-localizes and interacts with a component of the deadenylase 
complex CCR4–NOT, CNOT6 [276], suggesting that Wig-1 may enhance FAS mRNA 
degradation by enabling the interaction between FAS mRNA and the deadenylase complex. 
Supporting this hypothesis, we found Wig-1 or CNOT6 knockdown results in comparable 
increases in FAS mRNA levels. We conclude that FAS mRNA regulation is associated with 
altered deadenylation rate mediated by the CCR4–NOT complex. 
We could also demonstrate that Wig-1, CNOT6 and FAS mRNA localize simultaneously 
inside stress granules (SGs), cytoplasmic granules important in regulation of mRNA turnover 
upon stress-induced translational arrest [277]. We suggest that the co-localization of Wig-1, 
CNOT6 and FAS mRNA inside SGs facilitates the interaction between these three factors, 
enhancing FAS mRNA degradation and/or re-localization to other specialized mRNA 
degradation sites. 
The findings presented in this paper provide a better understanding of the biological function 
of Wig-1 protein and propose a role of Wig-1 in the AU-rich mediated decay via the 3’-to-5’ 
RNA decay pathway. Moreover we describe here that the Wig-1 ARE-BP in addition to 
being an RNA stabilizer (p53 and N-Myc) can also act as a destabilizer (FAS), in line with 
what reported for other ARE-BPs such as AUF1 and HuR [278-281]. 
Additionally, this is the first report that shows regulation of FAS mRNA stability at post-
transcriptional level. 
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In summary, the main findings of this paper are: 
• Wig-1 silencing affects a large set of mRNAs directly or indirectly 
•  Wig-1 acts as a survival factor promoting arrest rather than apoptosis 
•  Wig-1 binds and destabilizes FAS mRNA through an ARE on its 3’UTR 
•  Wig-1 interacts with the deadenylase complex CCR4-NOT and FAS mRNA in the 
cytoplasmic stress granules 
  
3.4 PAPER IV 
 
Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis 
 
In paper III we determined a list of mRNAs whose expression was affected by Wig-1, 
directly or indirectly. Another missing piece of the puzzle crucial in order to build an accurate 
model of cellular RNA-Wig-1 network was to probe the entire Wig-1-bound mRNA 
repertoire. In paper IV we have performed a systematic analysis of Wig-1-associated 
mRNAs, taking advantage from modern large-scale technologies. Through RNA 
immunoprecipitation followed by high-throughput sequencing (RIP-Seq) in HCT116 and 
Saos-2 cells, we found 286 Wig-1-bound mRNAs common in the two cell lines tested 
(HCT116 and Saos-2). In agreement with what we found in Paper III, FAS mRNA was found 
enriched in HCT116 cells. Network Enrichment Analysis indicated that Wig-1 targets are 
highly connected with the Cell Cycle pathways and is in accordance with what we described 
in Papers II and III.  
In order to validate the list of Wig-1-bound mRNAs, we selected nine Wig-1 associated 
mRNAs enriched in both HCT116 and Saos2 RIP-Seq experiments. We could validate 100% 
of the targets in the HCT116 cell line (CCNG1, RMI1, CHEK1, MTHFD2, CAV1, AMD1, 
HIF1A, MAD2L1 and EIF4E) and 67% of the targets in Saos-2 (MAD2L1, MTHFD2, 
RMI1, EIF4E, CHEK1 and AMD1). The difference in validation efficiency in the two cell 
lines can be explained by greater variation between replicates observed for Saos-2 as 
compared to HCT116, which generates large standard deviation and decrease the significance 
of the data. Despite this, we can appreciate in all selected targets a tendency that is 
concordant with what observed in the RIP-Seq results. Additionally, we found that Wig-1 
knockdown in HCT116 cells led to decreased levels of MTHFD2, EIF4E, RMI1, and CAV1 
mRNA while we observed an increase in the levels of HIF1A mRNA, all of which are 
important factors in tumor biology. These data underlines the role of Wig-1 in the regulation 
of cell cycle and cell proliferation, tumor onset, progression and metastasis. Our data 
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confirms that Wig-1 can both stabilize or destabilizes its RNA targets, including pro and anti-
proliferation factors.  
Our study helped also to further characterize Wig-1 mRNA-binding properties. Wig-1 
preferentially binds to mRNAs that carry AREs in their 3’UTRs as confirmed by the fact that 
95% of its bound targets mRNAs contain at least one AUUUA pentamer. Furthermore, de 
novo motif enrichment analysis revealed that Wig-1 favors the binding of motifs that are 
generally rich in A and Us compared to unbound control mRNAs.  
Both primary and secondary RNA structure elements are involved in describing protein/RNA 
interaction, therefore we decided to analyze whether the 3’UTR sequences of Wig-1-bound 
RNAs share a consensus secondary structures using the LocARNA software. We obtained a 
common consensus 2D motif shared among the nine validated targets that is characterized by 
very low GC content. Moreover the shared 2D motif is frequently situated in close proximity 
to an AU-rich element in the primary sequence of the 3’UTR or in the secondary folded 
structure on the 3’UTR. However, experimental validation of in silico predictions of 
structural elements is necessary since many factors other than nucleotides sequence can 
influence in vivo structure (e.g. binding of co-factors and solvent properties). 
Our work provides a comprehensive view of the RNA-binding properties of Wig-1 and helps 
to better define the Wig-1-RNA interacting network. Our data confirm that Wig-1 is an ARE-
BP involved in regulation of cell cycle progression and cell proliferation. Moreover, we 
significantly expand the list of known Wig-1 targets, and provide additional insights into 
preferred Wig-1 RNA binding motifs.  
 
To summarize, the main findings of this paper are: 
• Wig-1 binds more than two hundred mRNAs in HCT116 and Saos-2 cells  
• Wig-1 mRNA targets are functionally enriched in the cell cycle pathway 
• Wig-1 preferentially binds to mRNAs that carry AREs in their 3’UTRs, thus 
corroborating Wig-1 as an AU-rich element binding protein 
• Wig-1 bound mRNAs share a consensus 2D motif that might be important for Wig-1 
interaction. 
 
 
 
 

  33 
4 CONCLUSION AND FINAL DIRECTIONS 
 
I have been asked several times if Wig-1 is a good or bad guy. There is no simple answer to 
this question. The Wig-1 gene maps in a chromosomal area that is commonly amplified in 
cancer and its expression levels has also been found elevated in many tumor samples (Figure 
5 and [83]). This makes us believe that Wig-1 is behaving more as an oncogene than a tumor 
suppressor. Moreover, we show in this thesis that Wig-1 is stabilizing the mRNA levels of 
oncogenes such as N-Myc and possibly others like MAD2L1, MTHFD2 and EIF4E. But this 
is only part of the story. We believe that Wig-1 is a pro-survival factor and that it plays an 
important role in different processes depending on the cellular context.  
Wig-1 is a transcriptional target of the p53 tumor suppressor gene [5]. Its level increases after 
p53 activation and has a p53 response element on the promoter that resembles those of pro-
arrest p53 target genes (Figure 1) [45]. It has a defined role within the p53 pathway, which is 
to stabilize p53 mRNA levels and therefore to potentiate the p53 response to stress. At the 
same time Wig-1 directly regulates downstream targets of p53, such as 14-3-3! and FAS. 
Wig-1 promotes cell cycle arrest through induction of 14-3-3! whereas it reduces cell death 
promoting the decay of the pro-apoptotic FAS receptor. Moreover, a recent study showed that 
Wig-1 prevents senescence by promoting miRNA-mediated decay of the p53 target p21 
[282]. Thus, the induction of cell cycle arrest by Wig-1 may serve as a temporary pause 
during which cells can repair the damage and limit cell death. Concurrently, to prevent cells 
to undergo a terminal proliferation arrest, i.e. senescence, Wig-1 affects p21 decay. 
Additionally, Wig-1 may affect other downstream effects of the p53-dependent stress 
response by regulating additional p53 targets that we haven’t investigated or identified yet. 
For instance, we understand from Paper IV that Wig-1 binds and regulates HIF1A mRNA 
levels. HIF1A is a transcription factor that has an essential role in cellular and systemic 
responses to hypoxia and from previous publications we know that p53 negatively regulates 
both HIF1A transcriptional activity and HIF1A protein levels [283, 284]; furthermore, our 
data suggests that p53 might regulate HIF1A expression through its transcriptional target 
Wig-1. Therefore it would be interesting to examine if Wig-1 plays also a role in the 
regulation of hypoxia-induced p53-dependent apoptosis. 
Besides the key role of Wig-1 in modulating the p53 response to stress through regulation of 
p53 itself and components of the p53 pathway, we believe that Wig-1 carries out important 
functions in other critical cellular processes, specifically stem cell maintenance and 
differentiation [12]. Wig-1 is essential for cell proliferation and the effort to generate a Wig-1 
knockout mouse ended up giving some headaches, since we found Wig-1 deletion to be lethal 
as early as before blastocyst stage (unpublished results). Wig-1 expression levels decreases in 
cells that undergo differentiation as compared to the levels of their stem cells progenitors 
[106]. We also showed in Paper II that Wig-1 knockdown induces differentiation in 
neuroblastoma cells, and that in this particular case, this is attributable to Wig-1 mediated 
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regulation of N-Myc. Wig-1 expression is also regulated by a number of factors involved in 
differentiation and stem cell maintenance, such as the NGF, SPI1, ETS1, ELF1, MAX, BMI-
1 and p53 [107-112]. Intriguingly, Wig-1 promoter in mouse embryonic stem cells has been 
found to be a so called “bivalent promoter” meaning that it simultaneously bears both the 
activating (H3K4me3) and the repressive (H3K27me3) marks [26, 29]. These bivalent 
domains were first found in pluripotent embryonic stem cells and are considered to be a 
feature of developmentally regulated genes [285]. These genes are maintained repressed until 
the time when a particular differentiation signal will switch the activating mark on and 
engage the cell to develop into a more specific functional type. Following differentiation, 
bivalent promoters embrace either an active or a repressed state, depending on cell fate. 
Interestingly, our observation that Wig-1 level decreases in late passages primary fibroblast 
as compared to early-passage fibroblast suggests that Wig-1 might be downregulated in 
replicative senescence and perhaps chromatin repression is a trigger. Thus, epigenetic 
regulation of Wig-1 may affect its function depending on cell type, developmental stage and 
presence or absence of specific stimuli, making Wig-1 a very versatile, dynamic and context-
dependent effector.  
We have shown that Wig-1 has numerous targets that are involved in different pathways. 
Possibly, the above mentioned chromatin modification might also influence Wig-1 target 
selectivity and the outcome of the regulation of a specific mRNAs. Moreover, post-
translational modification (PTM) may also affect Wig-1 function, localization and stability as 
it is has been reported for a number of other ARE-BPs [253]. In our lab we are currently 
mapping Wig-1 PTMs and interesting data have been produced. Particularly, a number of 
modified sites are present exclusively in one of the two known Wig-1 species, suggesting that 
these different species might have different functions or properties (Xu et al., unpublished 
results). Additionally, some modified amino acids specifically located in the zinc finger 
domains, i.e. Wig-1 RNA binding motifs, are likely to be crucial for Wig-1 RNA-binding 
ability and might be affecting Wig-1 target selectivity. Further investigation will tell us which 
PTMs are central for Wig-1 function, under what circumstances and in what way they affect 
Wig-1 localization, stability, and more generally Wig-1-mediated post-transcriptional 
regulatory properties. 
The example of well-studied ARE-BPs denotes that protein-protein interaction is also 
relevant when deciding target choice and fate [286, 287]. In this thesis introduction I listed a 
number of protein that have been found to interact with Wig-1 (Table 1), although no studies 
have characterized the biological meaning of it, yet. Interestingly enough, we notice that 
several of these proteins are involved in mRNA processing, e.g. DICER1, SF3A1, 
hnRNPA2/B1 and TARBP2. Ahead of us, a good amount of lab work needs to be performed 
in order to obtain a clearer picture of Wig-1 protein interacting network. In paper IV we 
demonstrate Wig-1 interaction with CNOT6 protein [276], a component of the deadenylation 
complex, indicating a possible molecular mechanism for Wig-1-mediated ARE-dependent 
regulation.  
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Both Wig-1 overexpression and knockdown has a negative effect on cell viability, indicating 
the importance of monitoring and maintaining Wig-1 levels correctly balanced in the cell. 
This is most likely achieved through a well-coordinated regulatory system. Thanks to modern 
high-throughput methods, a lot of biological data are produced and shared everyday. Part of 
this information includes Wig-1 interaction with and/or regulation by transcription factors, 
miRNAs, and proteins involved in all aspect of gene regulation, from epigenetic to 
transcription, from mRNA turnover and translation to protein stability (Tables 1-4). The next 
challenge is to translate these data and generate biological models that would serve to gain 
further knowledge and understanding of the molecular basis behind relevant cellular 
processes, from tumor development to tumor progression, from embryonic development to 
senescence. 
So, coming back to the initial question: Is Wig-1 a good or a bad guy? If you have been 
reading so far, you are probably a life scientist and you might find this question a bit odd. 
There are no bad guys inside a cell in my opinion. There are, though, events that happen and 
disturb the harmony. Wig-1 is involved in maintaining this harmony and it does that together 
with p53. But Wig-1 does much more, and that “more” is so important that there is no life 
without Wig-1. 
.  
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gäng! Cisse, Örjan, Charone, Anna, Rasmus, Tjelvar, Lena, Amanda, Havde och 
Sebastian. Det betyder mycket för mig att ha er alla, TACK. 
Un grazie infinito alla mia famiglia in Italia. A mamma e papà per avermi sempre sostenuto 
e mai ostacolato nell’inseguire i miei sogni. Ai miei due fratelloni Luca e Marco per avermi 
sempre fatto sentire speciale. Alle mie cognatine Marica ed Elisa e alle mie dolcissime 
nipotine, Elena, Gaia, Chiara e Giorgia. 
To my dearest Markus. You are the most important discovery I made in these years !. 
Thank you for loving me so much, for understanding my needs, for not arguing when I 
needed to work over weekends or at late hours, for always listening to my frustrations, and 
celebrating with me the successes. Thanks for wanting to share the rest of your life with me.  
I love you. 
Olivia, my sweet little potato. You are our miracle. From the moment I could hold you in my 
arms I have become a better person. Thanks for coming to us.  
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